Bristol Myers Squibb (BMS) has entered into a massive strategic collaboration with China’s Hengrui Pharma, a deal that underscores a growing trend of Western pharmaceutical giants … Read more
Clinical trial data for a new pancreatic cancer treatment has revealed a significant breakthrough in patient survival, with results suggesting that a targeted daily pill from … Read more
The landscape of immunotherapy is undergoing a fundamental shift as CAR-T cell therapy, once the exclusive domain of late-stage cancer treatment, begins to demonstrate transformative potential … Read more
The Food and Drug Administration has once again denied approval for an experimental treatment for advanced skin cancer developed by Replimune Group, marking a second setback … Read more
A coalition of Senate Democrats is moving to prioritize a comprehensive overhaul of the American health care system, focusing heavily on the persistent issue of rising … Read more
Steve Ubl, the long-time leader of the Pharmaceutical Research and Manufacturers of America, is stepping down as CEO of the industry’s most influential trade group. Ubl, … Read more
The landscape of American drug manufacturing is facing a potential shift as the federal government moves to prioritize domestic production. In a novel budget blueprint for … Read more
For millions of people living with severe hyperlipidemia, the standard of care—statins and lifestyle changes—is often not enough. In some cases, genetic predispositions make cholesterol and … Read more
The federal government is reaching a critical statutory deadline today for the release of the 2027 Medicare Advantage payment regulation. This regulatory framework will serve as … Read more
The global pharmaceutical landscape is undergoing a significant shift, and China is rapidly emerging as a central player. For decades, the United States and Europe have … Read more
The ongoing clinical trials evaluating remdesivir as a treatment for COVID-19 are facing significant hurdles, primarily due to difficulties in enrolling enough eligible patients. This slowdown … Read more
